Literature DB >> 7887440

Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model.

B J Nickoloff1, S L Kunkel, M Burdick, R M Strieter.   

Abstract

Research into the cause and pathophysiological mechanisms underlying expression of psoriatric skin lesions has been hampered by lack of an appropriate animal model for this common and enigmatic cutaneous disease. These studies characterize normal skin, pre-psoriatic skin, and psoriatic plaque skin samples transplanted onto severe combined immunodeficiency mice. In this report we document that 1), normal, prepsoriatic, and psoriatic plaque keratome skin samples can be transplanted onto severe combined immunodeficiency mice reliably with high rates of graft survival (> 85%) and with reproducible changes consistently observed over prolonged periods of engraftment; 2), after transplantation, by clinical assessment and routine light microscopy, normal skin remained essentially normal whereas pre-psoriatic skin became thicker, and psoriatic plaque skin retained its characteristic plaque-type elevation and scale; 3), by using a panel of antibodies and immunohistochemical analysis, the overall phenotype of human cell types (including immunocytes) that persisted in the transplanted skin was remarkably similar to the immunophenotype of pretransplanted skin samples; 4), clearly recognized interface zones between human and murine skin within the epidermal and dermal compartments could be identified by routine microscopy and immunostaining, with focal areas of chimerism; and 5), elevated interleukin 8 cytokine levels were present in transplanted pre-psoriatic and psoriatic plaque skin samples. We conclude that there are many similarities between pre- and post-transplanted human samples of normal and psoriatic skin that are grafted onto severe combined immunodeficiency mice. Thus, we propose that this new animal model is appropriate for additional mechanistic-type studies designed to reveal the underlying genetic/etiological abnormality, as well as better illuminate the pathophysiological basis, for this important skin disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7887440      PMCID: PMC1869187     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  33 in total

1.  Psoriatic epidermal cells demonstrate increased numbers and function of non-Langerhans antigen-presenting cells.

Authors:  O Baadsgaard; A K Gupta; R S Taylor; C N Ellis; J J Voorhees; K D Cooper
Journal:  J Invest Dermatol       Date:  1989-02       Impact factor: 8.551

2.  Psoriasis and bone marrow transplantation.

Authors:  S N Jowitt; J A Yin
Journal:  BMJ       Date:  1990-05-26

3.  Clearance of severe psoriasis after allogenic bone marrow transplantation.

Authors:  D J Eedy; D Burrows; J M Bridges; F G Jones
Journal:  BMJ       Date:  1990-04-07

4.  Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders.

Authors:  R E Hammer; S D Maika; J A Richardson; J P Tang; J D Taurog
Journal:  Cell       Date:  1990-11-30       Impact factor: 41.582

5.  Identification of C5ades arg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales.

Authors:  J M Schröder; E Christophers
Journal:  J Invest Dermatol       Date:  1986-07       Impact factor: 8.551

6.  Genomic, phenotypic, and functional analyses of T cells in patients with psoriasis undergoing systemic cyclosporin A treatment.

Authors:  A Takashima; A Morita
Journal:  J Invest Dermatol       Date:  1991-03       Impact factor: 8.551

7.  Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis.

Authors:  B J Nickoloff; G D Karabin; J N Barker; C E Griffiths; V Sarma; R S Mitra; J T Elder; S L Kunkel; V M Dixit
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

8.  Monoclonal antibody MAC 387 recognizes a myelomonocytic antigen shared by epithelial cells in inflammatory skin diseases.

Authors:  N Kirkham; S J Peacock; D B Jones
Journal:  Br J Dermatol       Date:  1990-01       Impact factor: 9.302

9.  Characterization of skin-infiltrating lymphocytes in patients with psoriasis.

Authors:  A Nikaein; C Phillips; S C Gilbert; D Savino; A Silverman; M J Stone; A Menter
Journal:  J Invest Dermatol       Date:  1991-01       Impact factor: 8.551

10.  A study of factor XIIIa and MAC 387 immunolabeling in normal and pathological skin.

Authors:  R Cerio; J Spaull; G F Oliver; W E Jones
Journal:  Am J Dermatopathol       Date:  1990-06       Impact factor: 1.533

View more
  18 in total

1.  Development of a bioengineered skin-humanized mouse model for psoriasis: dissecting epidermal-lymphocyte interacting pathways.

Authors:  Sara Guerrero-Aspizua; Marta García; Rodolfo Murillas; Luisa Retamosa; Nuria Illera; Blanca Duarte; Almudena Holguín; Susana Puig; Maria Isabel Hernández; Alvaro Meana; Jose Luis Jorcano; Fernando Larcher; Marta Carretero; Marcela Del Río
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

2.  Crosstalk between keratinocytes and T cells in a 3D microenvironment: a model to study inflammatory skin diseases.

Authors:  Ellen H van den Bogaard; Geuranne S Tjabringa; Irma Joosten; Mieke Vonk-Bergers; Esther van Rijssen; Henk J Tijssen; Mirthe Erkens; Joost Schalkwijk; Hans J P M Koenen
Journal:  J Invest Dermatol       Date:  2013-10-11       Impact factor: 8.551

3.  Giant cell vasculitis is a T cell-dependent disease.

Authors:  A Brack; A Geisler; V M Martinez-Taboada; B R Younge; J J Goronzy; C M Weyand
Journal:  Mol Med       Date:  1997-08       Impact factor: 6.354

4.  Dermal injection of immunocytes induces psoriasis.

Authors:  T Wrone-Smith; B J Nickoloff
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

5.  Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis.

Authors:  B J Nickoloff; T Wrone-Smith
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

6.  Amphiregulin and epidermal hyperplasia: amphiregulin is required to maintain the psoriatic phenotype of human skin grafts on severe combined immunodeficient mice.

Authors:  Narasimharao Bhagavathula; Kamalakar C Nerusu; Gary J Fisher; Gao Liu; Archana B Thakur; Lorraine Gemmell; Shankar Kumar; Zenghai H Xu; Paul Hinton; Naoya Tsurushita; Nicholas F Landolfi; John J Voorhees; James Varani
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

7.  A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice.

Authors:  Daniel Voskas; Nina Jones; Paul Van Slyke; Celina Sturk; Wing Chang; Alex Haninec; Yael Olya Babichev; Jennifer Tran; Zubin Master; Stephen Chen; Nicole Ward; Maribelle Cruz; Jamie Jones; Robert S Kerbel; Serge Jothy; Lina Dagnino; Jack Arbiser; Giannoula Klement; Daniel J Dumont
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

8.  Tuberculin-induced delayed-type hypersensitivity reaction in a model of hu-PBMC-SCID mice grafted with autologous skin.

Authors:  A Tsicopoulos; J Pestel; O Fahy; H Vorng; F Vandenbusche; H Porte; L Eraldi; A Wurtz; H Akoum; Q Hamid; B Wallaert; A B Tonnel
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

9.  Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Authors:  P H Schafer; A Parton; A K Gandhi; L Capone; M Adams; L Wu; J B Bartlett; M A Loveland; A Gilhar; Y-F Cheung; G S Baillie; M D Houslay; H-W Man; G W Muller; D I Stirling
Journal:  Br J Pharmacol       Date:  2009-12-24       Impact factor: 8.739

Review 10.  Post-genomics and skin inflammation.

Authors:  Daniela Braconi; Giulia Bernardini; Annalisa Santucci
Journal:  Mediators Inflamm       Date:  2010-09-19       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.